Haleon plc (LSE:HLN) shares fell 2.90% to 327.80p at the close on Thursday, 1 October 2026, a decline of 9.80p from the previous close of 337.60p. The consumer healthcare group was among the FTSE 100 fallers as rising bond yields weighed on defensive stocks.
The decline leaves Haleon with a Market Capitalisation of approximately £29.70 billion.
Key Highlights
Haleon reported H1 2026 Revenue of £5,602 million, up 2.2% on a reported basis, with organic revenue growth of 2.6%.
Organic growth improved to 3.1% in the second quarter, from 2.2% in the first quarter, driven by North America.
Organic growth comprised 2.1% price and 0.5% volume/mix.
The adjusted Operating Margin improved to 24.3% from 22.7%, and the Interim Dividend was raised 9% to 2.4p.
Net Debt to adjusted EBITDA stood at 2.5 times, in line with medium-term guidance.
About Haleon plc
Haleon plc (LSE:HLN) is one of the world's largest consumer healthcare companies, formed through the demerger from GSK in 2022.
Its portfolio includes well-known brands such as Sensodyne, Advil, Centrum, Panadol, Voltaren, parodontax and Otrivin, spanning oral health, pain relief, vitamins and supplements, respiratory health and digestive health.
Haleon's Business is generally seen as defensive, because consumers continue buying everyday health products regardless of the economic cycle.
Why Is LSE:HLN Down Today?
The 2.90% decline to 327.80p came as global government bond yields surged. The UK 30-year gilt yield rose above 6% for the first time since 1998, and US Treasury yields reached multi-decade highs.
Defensive stocks such as Haleon are often valued as reliable, steady earners. When bond yields rise, these "bond-proxy" stocks can lose appeal, as investors are able to earn higher returns from government bonds.
Haleon also carries meaningful debt following its demerger, so higher interest rates can affect financing costs over time.
Key Reasons Behind the Downtick
The first Factor is the bond-proxy effect, which weighed on defensive consumer and healthcare stocks.
The second is slower organic growth. First-half organic growth of 2.6% was below the 3% to 5% full-year guidance range and lower than 3.2% in the prior-year period.
Third is weakness in Europe. Management said Europe remained a difficult market, with low-single-digit category declines and Haleon growth of only around 0.4%.
Fourth, respiratory health continued to weigh on results, reflecting category softness.
How the Wider Market Moved
The FTSE 100 fell 177.73 points to close at 10,428.27, its biggest one-day decline since May. While banks led the sell-off, defensive sectors including consumer staples and healthcare also lost ground.
Haleon's 2.90% fall was the smallest decline among the 20 largest FTSE 100 fallers on the day, reflecting its defensive characteristics. Consumer healthcare Demand is relatively stable, but the shares are still influenced by changes in interest rates because investors value predictable cash flows using discount rates linked to government bond yields. A sustained rise in yields can therefore weigh on valuations even when the underlying business is performing steadily.
Key Growth Catalysts
The strongest catalyst for LSE:HLN is an expected second-half acceleration. Management is confident of a stronger second half and has maintained its full-year guidance for 3% to 5% organic revenue growth.
North America drove improvement in the second quarter, helped by shelf resets and stronger execution.
Haleon is implementing a new operating model designed to improve agility and growth, and plans a step-up in Advertising and promotion investment.
Margin expansion and lower interest costs should support strong adjusted EPS growth, with adjusted operating profit expected to grow at a high single-digit rate at constant currency.
Risks
The main risk is weak consumer demand, particularly in Europe and in categories such as respiratory health.
Competition from private-label products, currency movements and Leverage are further considerations.
Failure to deliver the expected second-half acceleration could put pressure on guidance.
Valuation
At 327.80p, LSE:HLN is valued at around £29.7 billion. The interim dividend of 2.4p represents one-third of the prior-year dividend, in line with Haleon's policy.
The valuation reflects a high-quality, defensive business with improving margins, although rising bond yields have reduced the relative attractiveness of defensive stocks.
What Investors Should Watch Next
The Q3 trading update will show whether organic growth is accelerating towards the 3% to 5% guidance range.
Investors will watch North American performance, Europe trends and the impact of increased Marketing investment.
Margins, leverage and progress on the new operating model will also be important.
Overall, LSE:HLN's 2.90% fall to 327.80p reflects pressure on defensive stocks as bond yields surged. Haleon delivered improving second-quarter growth and stronger margins, but needs to deliver a second-half acceleration to meet its full-year guidance.






Please wait processing your request...